Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Resonance HealthASX:RHT Revenue per Share is A$0.03 as of Dec. 2025. The stock has 8 warning signs investors should review. Among 611 Healthcare Providers & Services companies, Resonance Health ranks better than 93.62% on this metric.
Resonance Health's revenue per share for the
six
months ended in Dec. 2025 was A$0.02.
Resonance Health's revenue per share for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.03.
During the past 12 months, the average Revenue Per Share Growth Rate of Resonance Health was 25.00% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was 44.20% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was 26.80% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was 12.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Resonance Health's Revenue per Share or its related term are showing as below:
ASX:RHT'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -12.6 Med: 7 Max: 81.7
Current: 44.2
During the past 13 years, Resonance Health's highest 3-Year average Revenue Per Share Growth Rate was 81.70% per year. The lowest was -12.60% per year. And the median was 7.00% per year.
ASX:RHT's 3-Year Revenue Growth Rate is ranked better than 93.62% of 611
companies
in the Healthcare Providers & Services industry
Industry Median: 6.9
vs ASX:RHT: 44.20
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Resonance Health Revenue per Share Related Terms
Resonance Health Revenue per Share Historical Data
* Premium members only.
The historical data trend for Resonance Health's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:RHT vs VEEV, BTSG, HQY: Revenue per Share Comparison
For the Health Information Services subindustry, Resonance Health's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Resonance Health PS Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Resonance Health's PS Ratio distribution charts can be found below:
* The bar in red indicates where Resonance Health's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Resonance Health's Revenue Per Share for the fiscal year that ended in Jun. 2025 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.03
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Resonance Health (ASX:RHT) has a Revenue per Share of A$0.03 as of Dec. 2025. Revenue per share equals the per-share value of a company's sales. View historical data on Resonance Health and its competitors. According to the industry distribution chart, Resonance Health ranks #39 out of 611 companies in the Healthcare Providers & Services industry, placing it in the top 6.4%.
Is Resonance Health's Revenue per Share too high?
Resonance Health's current Revenue per Share is A$0.03. Based on the distribution chart, Resonance Health ranks #39 out of 611 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers.
How does Resonance Health's Revenue per Share compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Resonance Health ranks #39 out of 611 companies for Revenue per Share. This places Resonance Health in the top 6% of its industry — outperforming the majority of peers. The industry median Revenue per Share is 6.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Healthcare Providers & Services company?
The median Revenue per Share among Healthcare Providers & Services companies is 6.90, based on 611 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Resonance Health and its competitors. For the Healthcare Providers & Services industry, the median Revenue per Share is 6.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Resonance Health's current Revenue per Share is A$0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Resonance Health stock overvalued right now?
Based on GuruFocus' analysis, Resonance Health (ASX:RHT) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.12, compared to a current price of A$0.06 — trading 50% below its estimated fair value. The current Revenue per Share is A$0.03. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Resonance Health (ASX:RHT), the current Revenue per Share is A$0.03 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Resonance Health Ltd is engaged in the development and commercialisation of software-as-medical-device (SaMD) technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. The Group's core SaMD product is FerriScan, a non-invasive liver analysis technology used for the assessment of iron in the liver. The Company also has several AI-assisted SaMDs including FerriSmart, HepaFatSmart, and LiverSmart. Its business segments are; SaMD1 which derives key revenue, Corporate, TrialsWest, and Resonance Clinica. Geographically, it generates maximum revenue from the Asia Pacific region and the rest from North America, and Europe, Middle East and Africa (EMEA) regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:RHT has been successfully added to your 
